Prof Peter Schmid presents data at the ESMO 2018 congress in Munich from the IMpassion130 trial.

This was a global, randomised, double-blind, phase 3 study of atezolizumab nab-paclitaxel vs placebo nab-paclitaxel in treatment-naive, locally advanced or metastatic triple-negative breast cancer.

For more on these findings, watch his interview with ecancer here.